

## Special Issue

# Harnessing the Immune System to Fight Pediatric Cancer

### Message from the Guest Editor

Pediatric cancer presents unique treatment challenges but also opportunities. Current treatment strategies typically involve the use of highly toxic drugs, which can result in life-long side effects. Treatment failure and relapse lead to increasingly worse outcomes and side effects from increasingly toxic therapies. Although children are not simply smaller adults, and pediatric cancers are fundamentally different in their etiology, treatments have largely been adapted from adult research. Pediatric cancers typically lack the large number of mutations that often make immunotherapy effective. However, genomic medicine offers the opportunity to identify genetic and, perhaps more importantly, epigenetic changes that might be targeted by molecular and immune-based therapies. This Special Issue will review how the genomes and epigenomes of pediatric patients are unique and potentially targetable. Identifying rare genetic and epigenetic variants that contribute to pediatric cancer will help to identify new treatment options. In addition, further development of immunotherapy for pediatric patients can improve the treatment paradigm and long-term outcomes for this unique population.

---

### Guest Editor

Dr. John M. Perry  
Children's Mercy Research Institute, Kansas City, MO, USA

---

### Deadline for manuscript submissions

closed (28 February 2023)



## Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/si/82951](https://mdpi.com/si/82951)

*Cells*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cells@mdpi.com](mailto:cells@mdpi.com)

[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)





# Cells

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 10.5  
Indexed in PubMed



[mdpi.com/journal/  
cells](https://mdpi.com/journal/cells)



## About the Journal

### Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

---

### Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,  
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,  
Copenhagen, Denmark

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).